Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advinus Therapeutics, an Indian pharmaceutical contract research organization, has announced drug discovery and development collaboration with US-based Ortho-McNeil-Janssen Pharmaceuticals, a provider of products to treat pain, acid reflux disease and infectious diseases.
Subscribe to our email newsletter
Under the agreement, Advinus and Ortho-McNeil-Janssen Pharmaceuticals (OMJPI) have agreed to develop drug candidates for various disease targets. Advinus will be responsible for drug discovery and early clinical development (until the completion of Phase IIa studies), while OMJPI will have an option to advance the drug candidates into late stage clinical trials and will be responsible for worldwide commercialization of the molecules.
As per the agreement, Advinus will receive an upfront payment and could receive milestone payments of up to $247 million upon successful development of two targets. Advinus is also eligible for royalties on the sales of any drug products resulting from the collaboration.
Kasim Mookhtiar, chief scientific officer of Advinus, said: “The collaboration provides a great opportunity to synergize the talent of Indian drug discovery and development scientists at Advinus with the scientific, clinical development and commercial strengths of a company like OMJPI for bringing new medicines to market with speed, efficiency and cost-effectiveness.”